In a study by Michele Ludici et al. in 2015, it was demonstrated that ILD affects almost 90% of Systemic Sclerosis (SSc) patients and is associated with decrease in Forced Vital Capacity (FVC), pulmonary fibrosis in HRCT, increase in serum level of IL-6, detectable serum level of anti-topoisomerase antibody, and diffuse skin involvement, which is consistent with the results of our study [22]. This evidence concerns the gene IL6 and pulmonary fibrosis.